Mesalazine Activates Adenosine Monophosphate-activated Protein Kinase: Implication in the Anti-inflammatory Activity of this Anti-colitic Drug / Heejung Park, Wooseong Kim, Dayoon Kim, Seongkeun Jeong, Yunjin Jung
Objective: Mesalazine, 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug that is most widely used for the treatment of Inflammatory Bowel Disease (IBD). Despite extensive clinical use, the exact pharmacological mechanism underlying the anti-colitic effects of 5-ASA has not yet been elucidated. A potential molecular mechanism underlying 5-ASA-mediated anti-colitic activity was investigated. Methods: An anti-inflammatory pharmacology of 5-ASA was scrutinized in human colon carcinoma cells and murine macrophages and in a TNBS-induced rat colitis model. Results: 5-ASA induced phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and its substrate acetyl-CoA carboxylase in cells. 5-ASA activation of AMPK occurred regardless of the presence of the pro-inflammatory mediators, Tumor Necrosis Factor Alpha (TNF-α) and lipopolysaccharide. 5-ASA inhibits TNF-α-dependent Nuclear Factor-Kappa B (NF-κB) activation, which was dampened by AMPK inhibition. Oral gavage of sulfasalazine (a colon-specific prodrug of 5- ASA) or rectal administration of 5-ASA ameliorated 2,4,6-trinitrobenzene sulfonic acid (TNBS)- induced rat colitis and activated AMPK in the inflamed colonic tissues while markedly diminishing the levels of NF-κB-regulated pro-inflammatory mediators cyclooxygenase-2, inducible nitric oxide synthase, and cytokine-induced neutrophil chemoattractant-3, elevated by the induction of inflammation. Rectal co-administration of 5-ASA and an AMPK inhibitor undermined 5-ASA-mediated activation of AMPK and its anti-colitic effects. Conclusion: These findings suggest that the activation of AMPK is involved in 5-ASA-mediated anticolitic effects at least partly via interference with pro-inflammatory NF-κB signaling.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Current molecular pharmacology - 12(2019), 4, Seite 272- |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Park, HeejungHeejung [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Umfang: |
1 Online-Ressource (9 p) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
KFL001024175 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL001024175 | ||
003 | DE-627 | ||
005 | 20231128165716.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210608s2019 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)KFL001024175 | ||
035 | |a (KFL)prod_DARH_.0E052A5C657721E4796D6911FD62821C10E40480 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Park, HeejungHeejung |e verfasserin |4 aut | |
245 | 1 | 0 | |a Mesalazine Activates Adenosine Monophosphate-activated Protein Kinase: Implication in the Anti-inflammatory Activity of this Anti-colitic Drug |c Heejung Park, Wooseong Kim, Dayoon Kim, Seongkeun Jeong, Yunjin Jung |
264 | 1 | |c 2019 | |
300 | |a 1 Online-Ressource (9 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Objective: Mesalazine, 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug that is most widely used for the treatment of Inflammatory Bowel Disease (IBD). Despite extensive clinical use, the exact pharmacological mechanism underlying the anti-colitic effects of 5-ASA has not yet been elucidated. A potential molecular mechanism underlying 5-ASA-mediated anti-colitic activity was investigated. Methods: An anti-inflammatory pharmacology of 5-ASA was scrutinized in human colon carcinoma cells and murine macrophages and in a TNBS-induced rat colitis model. Results: 5-ASA induced phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and its substrate acetyl-CoA carboxylase in cells. 5-ASA activation of AMPK occurred regardless of the presence of the pro-inflammatory mediators, Tumor Necrosis Factor Alpha (TNF-α) and lipopolysaccharide. 5-ASA inhibits TNF-α-dependent Nuclear Factor-Kappa B (NF-κB) activation, which was dampened by AMPK inhibition. Oral gavage of sulfasalazine (a colon-specific prodrug of 5- ASA) or rectal administration of 5-ASA ameliorated 2,4,6-trinitrobenzene sulfonic acid (TNBS)- induced rat colitis and activated AMPK in the inflamed colonic tissues while markedly diminishing the levels of NF-κB-regulated pro-inflammatory mediators cyclooxygenase-2, inducible nitric oxide synthase, and cytokine-induced neutrophil chemoattractant-3, elevated by the induction of inflammation. Rectal co-administration of 5-ASA and an AMPK inhibitor undermined 5-ASA-mediated activation of AMPK and its anti-colitic effects. Conclusion: These findings suggest that the activation of AMPK is involved in 5-ASA-mediated anticolitic effects at least partly via interference with pro-inflammatory NF-κB signaling | ||
700 | 1 | |a Kim, Wooseong |e verfasserin |4 aut | |
700 | 1 | |a Kim, Dayoon |e verfasserin |4 aut | |
700 | 1 | |a Jeong, Seongkeun |e verfasserin |4 aut | |
700 | 1 | |a Jung, Yunjin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d Sharjah : Bentham, 2008 |g 12(2019), 4, Seite 272- |h Online-Ressource |w (DE-627)KFL000006564 |w (DE-600)2433118-1 |w (DE-576)306836815 |x 1874-4702 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2019 |g number:4 |g pages:272- |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1874-4672&volume=12&issue=4&spage=272 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-BEJ | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
935 | |i IMPORT_0628_prod_DARH_02 | ||
951 | |a AR | ||
952 | |d 12 |j 2019 |e 4 |h 272- |